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Abstract
Background: This was an updated network meta-analysis (NMA) of anti-vascular endothelial growth factor (VEGF)
agents and laser photocoagulation in patients with diabetic macular edema (DME). Unlike previous NMA that used
meta-regression to account for potential confounding by systematic variation in treatment effect modifiers across
studies, this update incorporated individual patient-level data (IPD) regression to provide more robust adjustment.
Methods: An updated review was conducted to identify randomised controlled trials for inclusion in a Bayesian
NMA. The network included intravitreal aflibercept (IVT-AFL) 2 mg bimonthly (2q8) after 5 initial doses, ranibizumab
0.5 mg as-needed (PRN), ranibizumab 0.5 mg treat-and-extend (T&E), and laser photocoagulation. Outcomes
included in the analysis were change in best-corrected visual acuity (BCVA), measured using an Early Treatment
Diabetic Retinopathy Study (ETDRS) chart, and patients with ≥10 and ≥ 15 ETDRS letter gains/losses at 12 months.
Analyses were performed using networks restricted to IPD-only and IPD and aggregate data with (i) no covariable
adjustment, (ii) covariable adjustment for baseline BVCA assuming common interaction effects (against reference
treatment), and (iii) covariable adjustments specific to each treatment comparison (restricted to IPD-only network).
Results: Thirteen trials were included in the analysis. IVT-AFL 2q8 was superior to laser in all analyses. IVT-AFL 2q8
showed strong evidence of superiority (95% credible interval [CrI] did not cross null) versus ranibizumab 0.5mg PRN for
mean change in BCVA (mean difference 5.20, 95% CrI 1.90–8.52 ETDRS letters), ≥15 ETDRS letter gain (odds ratio [OR] 2.30,
95% CrI 1.12–4.20), and ≥10 ETDRS letter loss (OR 0.25, 95% CrI 0.05–0.74) (IPD and aggregate random-effects model with
baseline BCVA adjustment). IVT-AFL 2q8 was not superior to ranibizumab 0.5mg T&E for mean change in BCVA (mean
difference 5.15, 95% CrI -0.26–10.61 ETDRS letters) (IPD and aggregate random-effects model).
Conclusions: This NMA, which incorporated IPD to improve analytic robustness, showed evidence of superiority
of IVT-AFL 2q8 to laser and ranibizumab 0.5 mg PRN. These results were irrespective of adjustment for baseline BCVA.
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Background
Diabetic macular edema (DME) is the leading cause of vision
loss in patients with diabetic retinopathy [1]. Treatments in-
clude anti-vascular endothelial growth factor (VEGF) agents,
laser, steroids, and surgery. Anti-VEGF agents are currently
standard of care in DME treatment. These agents are known
to target underlying abnormalities in the VEGF signalling
cascade, which is a primary pathway in DME progression
[2]. Anti-VEGF agents reduce the incidence of legal blind-
ness, and their long-term efficacy and safety have been
proven in numerous randomised trials [3–8].
Direct randomised comparisons of anti-VEGF agents in
DME, however, are limited to the Diabetic Retinopathy Clin-
ical Research Network (DRCR.net) Protocol T trial [4, 8],
which only included ranibizumab at 0.3mg (US dose) and
did not include ranibizumab at 0.5mg (EU dose) and is
therefore not directly relevant to retina practice outside the
United States. Many comparator DME trials have also used
mean change in best-corrected visual acuity (BCVA; Early
Treatment Diabetic Retinopathy Study [ETDRS] letters)
after 12months as a primary efficacy measure, but differ-
ences in baseline BCVA between trials, a likely treatment ef-
fect modifier [4, 8], may confound indirect comparisons.
Previous network meta-analyses (NMA) of anti-VEGF
agents [9–11] have attempted to adjust for baseline BCVA
using aggregate data. These analyses provide useful data for
decision-making, but meta-regression based on aggregate
data may not mirror effects at the patient level and could
also be confounded by non-linear covariable effects and
other sources of heterogeneity between trials that are not
accounted for by the variables included in the meta-regres-
sion [12, 13]. This bias is known as ecological bias.
The European Medicines Agency has recently issued a
policy with a primary objective of making clinical reports
and individual patient-level data (IPD) available to enable
public scrutiny and allow for the application of new know-
ledge in future research [14]. Within-trial regression ana-
lysis based on IPD provides more robust adjustment for
differences in BCVA between trials. However, to our
knowledge, no published NMA has incorporated IPD.
The objective of this NMA was to perform an updated
indirect comparison of the efficacy of approved
anti-VEGF regimens and laser photocoagulation in DME
based on mean change in BCVA and gain or loss of let-
ters at 12 months. The NMA incorporated both aggre-
gate data and IPD, where available. Different regimens,
including fixed, as-needed (PRN), and treat-and-extend
(T&E), were also included. These regimens have not
been incorporated in detail in previous NMAs.
Methods
Search strategy
The literature search was updated from a previous sys-
tematic literature review performed in February 2015
[9]. This updated literature review identified all relevant
randomised controlled trials (RCTs) that were published
from February 2015 to December 2016 using the same
search strategy that was described in the previous publi-
cation [9]. An additional search of ClinicalTrials.gov
(from January 2015 to December 2016) was also per-
formed to identify any new trials. This was performed by
searching for ‘diabetic macular edema phase III RCT’ to
be consistent with the previous analysis. As summarized
in Fig. 1, the analysis presented here uses data from all
studies identified above.
Inclusion criteria
Trials were screened using the populations, interven-
tions, comparators, outcomes, and study design (PICOS)
criteria as defined in the previous publication [9]. This
approach also applied to the results from the Clinical-
Trials.gov search. Only trials that reported the rando-
mised controlled results at 12 months for mean change
from baseline in BCVA (ETDRS letters) (continuous
outcome), and the proportion of patients achieving gain/
loss of ≥10 and ≥ 15 ETDRS letters (binary outcomes)
were included.
Treatment regimens of interest for European practice
were IVT-AFL 2mg every 8 weeks (2q8) after 5 initial
doses, ranibizumab 0.5 mg PRN, ranibizumab 0.5 mg
T&E, and laser photocoagulation. Because it is not li-
censed for ophthalmic use, bevacizumab was not in-
cluded in the analysis. Treatments were grouped
according to dose, number of loading doses, regimen,
which could be proactive (fixed), reactive (PRN), or pro-
active/reactive (T&E), and median number of injections.
Treatment regimens for ranibizumab and IVT-AFL were
not the same because treatment regimens were deter-
mined by the individual study sponsors. These groupings
were used for treatment classification in the NMA. All
included trials were compliant with the Declaration of
Helsinki, had protocols approved by relevant country-
and trial-specific institutional review boards/independ-
ent ethics committees, and enrolled patients who pro-
vided written informed consent for participation.
Data extraction
Data extraction was based on methods described previ-
ously [9]. Missing standard errors (SEs) for the change
in continuous outcome were imputed using the follow-
ing equation [15]:
SEchange ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SD2baseline þ SD2final− 2 correlation SDbaseline  SDfinal
 
q
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
sample size
p
ð1Þ
Where SDfinal was not available, SDbaseline was used in
place of SDfinal. For the correlation, 0.5 was used in the
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formula above; this has been described as a conservative
assumption [16]. Standard deviation (SD) and 95% confi-
dence intervals (CIs) were converted to SEs based on
established formulas ([15]. If CI, SD, and SE were not re-
ported and only P values were available, it was assumed
that the P values were calculated using a Wald test. The
SE was then calculated by rearranging the formula for
calculating P values for normally distributed variables.
Analyses
The trials were used to form a Bayesian NMA for con-
tinuous and binary outcomes. Analyses were performed
using IPD-only and IPD and aggregate data networks
with (i) no covariable adjustment, (ii) covariable adjust-
ment for baseline BVCA assuming common interaction
effects (against reference treatment), and (iii) covariable
adjustments specific to each treatment comparison
(IPD-only). Both fixed-effect and random-effects models
were fitted.
Baseline BCVA was identified as the main treatment
effect modifier (covariable) for vision-related outcomes,
and was controlled for in the NMA. Based on previous
analysis of IPD from the VIVID-DME and VISTA-DME
trials, other potential covariables (diabetic retinopathy
severity scale, prior anti-VEGF treatment, baseline gly-
cated haemoglobin, blood pressure treatment, and cata-
racts) did not have a significant impact on IVT-AFL
treatment effects and were not included [17–21]. Base-
line central retinal thickness (CRT) was shown to be a
potential treatment effect modifier on vision-related out-
comes when receiving IVT-AFL treatment [22]; however,
it was excluded as it was found to be highly correlated
with baseline BCVA, which would have resulted in
co-linearity in the model. An additional file contains fur-
ther information on the models and covariable adjust-
ment (see Additional file 1: Appendix 1).
The analyses were conducted with OpenBUGS version
3.2.3 using Monte Carlo chain simulations to calculate
posterior distributions for the parameters of interest. A
Monte Carlo error of less than 5% of the posterior SD in-
dicated acceptable simulation error [23]. The absolute and
relative model fits were assessed using residual deviance
Fig. 1 Flow chart summarizing the literature search
Muston et al. BMC Ophthalmology          (2018) 18:340 Page 3 of 11
and deviance information criterion statistics. Convergence
was assessed by visual inspection of caterpillar and prob-
ability density plots and by running analyses using 3 separ-
ate chains to ensure that all chains converged to the same
distribution. We ran all models with a burn-in of 50,000
and 200,000 iterations.
All baseline and intervention parameters were given
vague normal (mean = 0, SD = 1000) distributions, an ap-
propriately large range given the scale of measurement.
A binomial likelihood with logit link function was used
for binary data, and a normal likelihood with identity
link function was used for continuous data. The Open-
BUGS codes used were adapted from previously pub-
lished codes [24]. This allowed the code to be easily
adapted to include IPD. The methodology also followed
guidance from the International Society for Pharmacoe-
conomics and Outcomes Research Task Force on Indir-
ect Treatment Comparisons [25, 26].
Binary outcomes were reported as odds ratios (ORs),
and the continuous outcome was reported as the mean
treatment difference (ETDRS letters). Uncertainty was
reported using 95% credible intervals (CrIs). IVT-AFL
2q8 was chosen as the reference treatment so that it
could be compared with all treatments of interest (ie,
ranibizumab 0.5 mg PRN, ranibizumab 0.5 mg T&E, and
laser photocoagulation).
Results
Networks
A total of 13 trials were identified as eligible for inclusion
[4–7, 27–33]. The treatment regimens in these trials were
classified and included in the NMA as summarised in
Additional file 2: Appendix 2; an overview of the outcomes
reported in these trials is summarised in Additional file 3:
Appendix 3. Thirteen trials provided continuous outcome
data (ie, mean change in BCVA) and 10 trials provided bin-
ary outcome data (ie, proportion of patients with loss/gain
of ≥10 and/or ≥ 15 ETDRS letters) as summarised in
Table 1. Baseline BCVA was adjusted for by incorporating
IPD from 5 trials and aggregate data from 8 trials. IPD-only
and IPD and aggregate data networks were developed using
these data, which are summarised in Fig. 2.
In all analyses, IVT-AFL 2q8 was shown to be superior
to laser. Overall, the means for the coefficients describing
the interactions effects were negative (see Additional file 1:
Appendix 1) indicating that patients with lower BCVA at
baseline had a greater response to treatment. Only
random-effects IPD and aggregate models are described
here.
Mean change in BCVA (continuous outcome)
The results for the mean change in BCVA (ETDRS let-
ters) from the analysis of the IPD-only and IPD and ag-
gregate data networks are shown in Table 2. IVT-AFL
2q8 showed strong evidence of superiority (95% CrI did
not cross 0) versus laser, ranibizumab 0.5 mg PRN, and
ranibizumab 0.5 mg PRN with laser in the IPD and ag-
gregate networks (all covariable adjustments) for mean
change in BCVA. The mean difference (95% CrI) in
BCVA (ETDRS letters) for IVT-AFL 2q8 versus ranibi-
zumab 0.5 mg PRN was 5.15 (1.82–8.54) (no covariable
adjustment) and 5.20 (1.90–8.52) (common covariable
adjustment). IVT-AFL 2q8 was not superior to ranibizu-
mab 0.5 mg T&E for mean change in BCVA (mean dif-
ference 5.15; 95% CrI -0.26–10.61 ETDRS letters) (IPD
and aggregate random-effects model).
Proportion of patients gaining or losing ≥10 and ≥ 15
ETDRS letters (binary outcomes)
The IPD-only and IPD and aggregate data network results
for letter gains are shown in Table 3. IVT-AFL 2q8
showed strong evidence of superiority (95% CrI did not
cross 1) for the proportion of patients gaining ≥15 ETDRS
letters versus laser, ranibizumab 0.5mg PRN, ranibizumab
0.5 mg PRN with laser, and ranibizumab 0.5mgT&E with
laser in the IPD and aggregate networks (all covariable ad-
justments). The OR (95% CrI) for gaining ≥15 ETDRS let-
ters for IVT-AFL 2q8 versus ranibizumab 0.5 mg PRN
was 2.08 (1.06–3.70) (no covariable adjustment) and 2.30
(1.12–4.20) (common covariable adjustment).
The IPD-only and IPD and aggregate data network re-
sults for the proportion of patients losing ≥10 and ≥ 15
ETDRS letters are shown in Table 4. IVT-AFL 2q8
showed strong evidence of superiority (95% Crl did not
cross 1) for reducing the proportion of patients losing
≥10 or ≥ 15 ETDRS letters versus laser. IVT-AFL 2q8
was also superior to ranibizumab 0.5 mg PRN, ranibizu-
mab 0.5 mg PRN with laser, and ranibizumab 0.5 mg
Table 1 Overview of trial data included in each analysis [4–8, 27–32]
IPD and aggregate network IPD-only network
DRCR.net Protocol I DRCR.net Protocol I
DRCR.net Protocol J DRCR.net Protocol J
DRCR.net Protocol T VISTA-DME
LUCIDATEa VIVID-DME
RESPONDb VIVID-EAST
RESTORE
RETAIN
REVEAL
RIDEa
RISEa
VISTA-DME
VIVID-DME
VIVID-EAST
aLUCIDATE, RISE and RIDE did not provide data for letter gains/losses
bRESPOND did not provide data for letter losses
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Fig. 2 (See legend on next page.)
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T&E in the IPD and aggregate networks (all covariable ad-
justments) for reducing ≥10 ETDRS letter losses. The OR
(95% Crl) for losing ≥10 ETDRS letters for IVT-AFL
2q8 versus ranibizumab 0.5 mg T&E was 0.19 (0.00–
0.96) (no covariable adjustment) and 0.21 (0.00–0.97)
(common covariable adjustment). However, a number
of OR values calculated were implausible, which may
be attributable to reduced evidence supporting com-
parison for ETDRS letters in Table 3 and Table 4.
These implausible values are limited to certain ana-
lyses of the IPD-only dataset, and may be a result of
the methodology employed.
(See figure on previous page.)
Fig. 2 IPD-only and IPD and aggregate data networks for (a) mean change in BCVA (continuous outcome) and (b) gain/loss of ≥10 and≥ 15
ETDRS letters (binary outcomes). 2q8, every 8 weeks; BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; IPD,
individual patient-level data; IVTA, intravitreal triamcinolone acetonide; IVT-AFL, intravitreal aflibercept; PRN, as-needed; q4, every 4 weeks; T&E,
treat-and-extend. aRESPOND did not provide data for letter losses. Note: outcomes for ranibizumab 0.3 mg (US dose), intravitreal triamcinolone
acetonide and bevacizumab are not reported
Table 2 IPD-only and IPD and aggregate network results for mean change in BCVA (ETDRS letters)
IPD-only network IPD and aggregate network
Comparison Covariable adjustment Model Mean difference 95% Crl Mean difference 95% Crl
IVT-AFL 2q8 vs laser None Fixed + 10.32a 8.31–12.34 + 10.32a 8.30–12.35
Random + 10.47a 6.92–14.16 + 10.45a 7.81–13.12
Common (baseline BCVA) Fixed + 10.30a 8.82–11.78 + 10.27a 8.79–11.74
Random + 10.54a 7.07–14.42 + 10.47a 7.88–13.11
Treatment-specific Fixed + 10.48a 8.99–11.97 – –
Random + 10.65a 7.13–14.34
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN None Fixed + 3.92a 0.60–7.24 + 4.42a 2.07–6.76
Random + 3.47 −3.14–10.44 + 5.15a 1.82–8.54
Common (baseline BCVA) Fixed + 3.14a 0.48–5.80 + 4.95a 3.09–6.83
Random + 3.54 −2.93–10.81 + 5.20a 1.90–8.52
Treatment-specific Fixed + 3.09a 0.44–5.72 – –
Random + 3.38 −3.20–10.18
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser None Fixed + 5.96a 2.65–9.25 + 5.17a 2.73–7.61
Random + 6.05a 0.45–12.19 + 5.95a 2.60–9.37
Common (baseline BCVA) Fixed + 5.71a 3.11–8.29 + 5.77a 3.81–7.74
Random + 6.16a 0.67–12.55 + 6.00a 2.66–9.36
Treatment-specific Fixed + 5.68a 3.06–8.29 – –
Random + 6.03a 0.51–11.94
IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E None Fixed – – + 5.06a 1.88–8.23
Random + 5.07 −0.37–10.54
Common (baseline BCVA) Fixed – – + 4.90a 2.06–7.72
Random + 5.15 −0.26–10.61
Treatment-specific Fixed – – – –
Random
IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E + laser None Fixed – – + 5.07a 2.00–8.13
Random + 3.80 − 1.57–9.25
Common (baseline BCVA) Fixed – – + 3.65a 0.94–6.35
Random + 3.90 −1.42–9.25
Treatment-specific Fixed – – – –
Random
aIVT-AFL showed statistical superiority to the comparator as 95% CrI ranges did not cross 0
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Table 3 IPD-only and IPD and aggregate network results for proportion of patients gaining ≥10 and ≥ 15 ETDRS letters
Gain ≥10 ETDRS letters Gain ≥15 ETDRS letters
IPD-only network Comparison Covariable adjustment Model OR 95% Crl OR 95% Crl
IVT-AFL 2q8 vs laser None Fixed 4.82a 3.52–6.46 4.97a 3.32–7.26
Random 18.72a 1.16–20.20 5.76a 1.97–12.24
Common (baseline BCVA) Fixed 4.96a 3.57–6.73 5.49a 3.47–8.38
Random 60.90a 1.06–26.91 7.58a 1.79–15.34
Treatment-specific Fixed 5.10a 3.67–6.94 5.64a 3.55–8.66
Random 7.28a 1.16–24.20 534.90a 1.85–19.79
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN None Fixed 2.10a 1.19–3.45 2.59a 1.29–4.69
Random 93,680.00 0.10–29.60 10.68 0.53–14.63
Common (baseline BCVA) Fixed 2.09a 1.15–3.48 2.85a 1.35–5.35
Random 32.25 0.08–42.16 59.97 0.37–20.4
Treatment-specific Fixed 1.99a 1.07–3.38 3.06a 1.43–5.85
Random 594.80 0.14–43.29 2056.00 0.43–39.48
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser None Fixed 3.04a 1.82–4.77 2.74a 1.44–4.78
Random 22.24 0.29–31.29 5.93 0.76–13.29
Common (baseline BCVA) Fixed 2.92a 1.70–4.68 2.88a 1.44–5.23
Random 969.00 0.28–41.36 10.13 0.59–16.11
Treatment-specific Fixed 2.99a 1.73–4.81 2.99a 1.48–5.44
Random 22.32 0.37–47.51 52.20 0.60–23.38
Gain ≥10 ETDRS letters Gain ≥15 ETDRS letters
IPD and aggregate network Comparison Covariable adjustment Model OR 95% Crl OR 95% Crl
IVT-AFL 2q8 vs laser None Fixed 4.82a 3.52–6.45 4.97a 3.32–7.28
Random 5.06a 2.39–9.49 5.03a 3.09–7.88
Common (baseline BCVA) Fixed 4.93a 3.55–6.72 5.58a 3.52–8.58
Random 5.27a 2.44–9.91 5.62a 3.28–9.15
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN None Fixed 1.72a 1.11–2.53 2.07a 1.19–3.38
Random 1.76 0.62–3.94 2.08a 1.06–3.70
Common (baseline BCVA) Fixed 1.71a 1.09–2.56 2.28a 1.25–3.85
Random 1.79 0.63–4.06 2.30a 1.12–4.20
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser None Fixed 2.01a 1.32–2.94 2.11a 1.22–3.42
Random 2.18 0.81–4.78 2.14a 1.12–3.76
Common (baseline BCVA) Fixed 1.96a 1.26–2.92 2.27a 1.26–3.83
Random 2.20 0.81–4.90 2.31a 1.15–4.20
IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E None Fixed 1.57 0.76–2.86 1.78 0.76–3.55
Random 1.88 0.30–6.26 1.86 0.63–4.18
Common (baseline BCVA) Fixed 1.55 0.75–2.85 1.96 0.81–4.00
Random 1.95 0.32–6.47 2.04 0.67–4.77
IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E + laser None Fixed 2.41a 1.15–4.48 3.22a 1.32–6.68
Random 2.88 0.47–9.68 3.35a 1.09–7.84
Common (baseline BCVA) Fixed 2.39a 1.13–4.48 3.56a 1.42–7.53
Random 3.02 0.48–9.87 3.73a 1.16–8.88
aIVT-AFL showed statistical superiority to the comparator as 95% CrI ranges did not cross 1
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Table 4 IPD-only and IPD and aggregate network results for patients losing ≥10 and≥ 15 ETDRS letters
Loss ≥10 ETDRS letters Loss ≥15 ETDRS letters
IPD-only network Comparison Covariable adjustment Model OR 95% Crl OR 95% Crl
IVT-AFL vs laser None Fixed 0.06a 0.02–0.12 0.04a 0.01–0.112
Random 0.11a 0.01–0.29 0.22a 0.00–0.28
Common (baseline BCVA) Fixed 0.06a 0.02–0.12 0.04a 0.00–0.11
Random 0.19a 0.01–0.27 0.07a 0.00–0.24
Treatment-specific Fixed 0.05a 0.02–0.11 0.02a 0.00–0.08
Random 0.08a 0.01–0.24 0.04a 0.00–0.16
IVT-AFL vs ranibizumab 0.5 mg PRN None Fixed 0.37 0.07–1.22 0.51 0.02–2.51
Random 92.49 0.01–8.70 278,400.00 0.00–39.31
Common (baseline BCVA) Fixed 0.37 0.07–1.24 0.47 0.02–2.34
Random 483.00 0.01–6.20 825.00 0.00–22.22
Treatment-specific Fixed 0.51 0.07–2.07 0.45 0.00–2.59
Random 9.28 0.01–7.53 300.00 0.00–15.68
IVT-AFL vs ranibizumab 0.5 mg PRN + laser None Fixed 0.17a 0.04–0.44 0.23a 0.02–0.91
Random 6.74 0.01–2.11 74.93 0.00–7.32
Common (baseline BCVA) Fixed 0.18a 0.04–0.47 0.20a 0.02–0.81
Random 12.89 0.01–1.75 11.07 0.00–5.17
Treatment-specific Fixed 0.18a 0.04–0.51 0.13a 0.00–0.65
Random 3.38 0.01–1.89 5.42 0.00–3.04
Loss ≥10 ETDRS letters Loss ≥15 ETDRS letters
IPD and aggregate network
Comparison
Covariable adjustment Model OR 95% Crl OR 95% Crl
IVT-AFL 2q8 vs laser None Fixed 0.06a 0.02–0.12 0.04a 0.00–0.12
Random 0.06a 0.02–0.14 0.04a 0.00–0.14
Common (baseline BCVA) Fixed 0.06a 0.02–0.12 0.04a 0.00–0.11
Random 0.06a 0.02–0.14 0.04a 0.00–0.13
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN None Fixed 0.24a 0.07–0.60 0.31 0.02–1.15
Random 0.25a 0.05–0.73 0.36 0.02–1.49
Common (baseline BCVA) Fixed 0.24a 0.07–0.59 0.28 0.02–1.05
Random 0.25a 0.05–0.74 0.33 0.02–1.39
IVT-AFL 2q8 vs ranibizumab 0.5 mg PRN + laser None Fixed 0.14a 0.04–0.33 0.11a 0.01–0.37
Random 0.15a 0.03–0.41 0.13a 0.01–0.47
Common (baseline BCVA) Fixed 0.14a 0.04–0.33 0.10a 0.01–0.34
Random 0.15a 0.03–0.41 0.11a 0.01–0.43
IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E None Fixed 0.15a 0.01–0.75 0.33 0.00–1.94
Random 0.19a 0.00–0.96 0.81 0.00–3.00
Common (baseline BCVA) Fixed 0.15a 0.00–0.73 0.30 0.00–1.74
Random 0.21a 0.00–0.97 0.54 0.00–2.67
IVT-AFL 2q8 vs ranibizumab 0.5 mg T&E + laser None Fixed 222,500.00 0.03–607.2 201,200.00 0.02–671.3
Random 325,000.00 0.02–589.9 130,000.00 0.01–751.0
Common (baseline BCVA) Fixed 470,400.00 0.03–555.1 3,311,000.00 0.02–592.0
Random 662,700.00 0.02–622.8 2,877,000.00 0.01–775.5
aIVT-AFL showed statistical superiority to the comparator as 95% CrI ranges did not cross 1
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Discussion
It is important for physicians and policymakers to com-
pare the relative efficacy of DME treatments using the
most robust methods available. Although direct head-
to-head comparative trials provide stronger internal
validity than indirect comparisons, there are a small
number of these trials in DME (eg, DRCR.net Protocol T)
[4, 8], and there are no direct randomised comparative
trial outcomes of IVT-AFL 2q8 and ranibizumab 0.5mg
(any regimen) available. The objective of this NMA was to
perform an updated indirect comparison of IVT-AFL 2q8
versus relevant comparators, including ranibizumab 0.5
mg, from a previous publication [9]. Notably, this NMA
incorporated IPD where available and adjusted for base-
line BCVA, which is a known and important treatment ef-
fect modifier. To our knowledge, this is also the first
NMA in DME that adjusted for any imbalance of treat-
ment effect modifiers using IPD. Previous analyses that
used only aggregate data are prone to ecological bias.
In the IPD and aggregate random-effects models,
IVT-AFL 2q8 (after 5 monthly loading doses) showed
strong evidence of superiority versus laser and ranibi-
zumab 0.5 mg PRN with/without laser for mean
change in BCVA from baseline and for gain of ≥15
ETDRS letters. IVT-AFL 2q8 also showed strong evi-
dence of superiority for reducing ≥10 ETDRS letter
losses versus ranibizumab 0.5 mg PRN with/without
laser and versus ranibizumab 0.5 mg T&E. These re-
sults were consistent regardless of whether adjustment
was made for baseline BCVA.
The BCVA results are similar to those in the previ-
ously published NMA that included fewer trials and did
not include IPD [9]. In this previous NMA, there was an
increase in mean BCVA at 12months with IVT-AFL 2q8
over ranibizumab 0.5 mg PRN of 4.67 letters (95% CrI
1.85–7.52) in the random-effects Bayesian model (10
trials). However, there was no significant difference
between IVT-AFL 2q8 versus ranibizumab 0.5mg PRN for
gain of ≥15 ETDRS letters (OR 1.87, 95% Crl 0.87–4.16) or
loss of ≥10 ETDRS letters (OR 0.26, 95% Crl 0.05–1.31) in
the random-effects Bayesian model (6 trials). The BCVA re-
sults are also consistent with those in a recent NMA that
used an aggregate data approach [34]. This NMA of 21 tri-
als (4307 eyes), which compared 11 different DME inter-
ventions including IVT-AFL and ranibizumab 0.5mg,
showed that IVT-AFL was the most favourable treatment
at 12months with respect to improvements in BCVA (OR
8.19, 95% CrI 5.07–11.96) and central macular thickness
(OR -110.83, 95% CrI -190.25 to − 35.27) [34].
The availability and use of IPD can be important for
ensuring that NMAs provide more robust adjustment
for differences in between-trial baseline BCVA. In our
NMA, we showed that adjustment for baseline BCVA
did not affect the results in any model, but a lower
BCVA at baseline was associated with a greater response
to treatment. These findings are comparable with those
observed in DRCR.net Protocol T [4]. In DRCR.net
Protocol T, the mean change in visual acuity score
(VAS) at 12 months was greater in patients with a lower
BCVA score at baseline; for patients with baseline VAS
of 74–78, the mean change in VAS was ~ 7 letters
(IVT-AFL 2mg) and ~ 6.5 letters (ranibizumab 0.3 mg)
at 12months, and for patients with baseline VAS of 24–53
letters the mean change in VAS was ~ 25 letters (IVT-AFL
2mg) and ~ 17.5 letters (ranibizumab 0.3mg) [4]. Similar
findings were observed in a post hoc analysis of the
VISTA-DME and VIVID-DME trials, IVT-AFL 2q8 treat-
ment resulted in slightly better 12-month visual acuity
outcomes in patients with baseline BCVA of ≥39 to ≤60
letters compared with those with a baseline BCVA of ≥61
to ≤73 letters; the mean change with IVT-AFL 2q8 at 12
months was 11.3 ETDRS letters (VIVID-DME) and 11.4
ETDRS letters (VISTA-DME) (baseline BCVA of ≥39 to
≤60 letters) and 8.6 ETDRS letters (VIVID-DME) and 9.5
ETDRS letters (VISTA-DME) (baseline BCVA of ≥61 to
≤73 letters) [35].
The comparison of IVT-AFL 2q8 versus ranibizumab
0.5 mg (PRN and T&E) also provides a useful comple-
ment to the direct comparative evidence of IVT-AFL 2
mg versus ranibizumab 0.3 mg from DRCR.net Protocol
T [4, 8]. The EURETINA guidelines question the extent
to which the slower effect of ranibizumab seen in
DRCR.net Protocol T compared with IVT-AFL is attrib-
utable to the lower dose used [36]. This outcome is
consistent with those in other published NMAs [9, 37].
In an updated Cochrane analysis of 24 trials (6007 pa-
tients with DME) [37], DME patients receiving ranibi-
zumab (0.3 mg and 0.5 mg monthly) were less likely to
gain ≥3 lines of visual acuity at 1 year compared with
IVT-AFL (risk ratio [RR] 0.75, 95% CI 0.60–0.94). At 1
year, the visual acuity and CRT were worse with ranibi-
zumab compared with IVT-AFL (mean difference in
visual acuity: 0.08 logMAR, 95% CI 0.05–0.11; mean
difference in CRT: 39 μm, 95% CI 2–76). It should be
noted that ranibizumab 0.3 mg and 0.5 mg monthly
were merged into 1 group as no heterogeneity was sus-
pected between studies using these regimens in this
Cochrane analysis. These authors concluded that the dif-
ference between IVT-AFL and ranibizumab was consist-
ent with indirect evidence using ranibizumab 0.5mg.
Despite the robust approach used in the current ana-
lysis, there are still some limitations associated with this
updated NMA. We did not consider safety outcomes or
longer-term efficacy outcomes, and there was limited
availability of IPD in the public domain. Outcomes could
also have been improved with the replacement of aggre-
gate data from some trials (such as DRCR.net Protocol
T) with IPD; however, the availability of IPD from
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DRCR.net Protocols I and J in addition to VIVID-DME,
VISTA-DME, and VIVID-EAST enabled sufficient IPD
to be included.
Conclusions
This NMA, which incorporated aggregate data and IPD
to improve model robustness, consistently showed evi-
dence of superiority of IVT-AFL 2q8 to laser and ranibi-
zumab 0.5 mg PRN with/without laser for mean change
in BCVA, gain of ≥15 ETDRS letters, and loss of ≥10
ETDRS letters at 12 months. IVT-AFL 2q8 was also su-
perior to ranibizumab 0.5 mg T&E for loss of ≥10
ETDRS letters. These efficacy results were consistent ir-
respective of adjustment for baseline BCVA. Comparison
of IVT-AFL 2q8 versus ranibizumab 0.5 mg PRN and
T&E provides a useful complement to the direct com-
parative evidence of IVT-AFL 2mg versus ranibizumab
0.3 mg given in DRCR.net Protocol T. It is hoped that
these data will be of additional benefit to those involved
in the care of DME patients and to policymakers inter-
ested in developing future NMAs.
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